| Literature DB >> 27426301 |
Jia-Cheng Li1, Juan Zhang2, Mosar Corrêa Rodrigues2, De-Jun Ding3, João Paulo Figueiró Longo2, Ricardo Bentes Azevedo2, Luis Alexandre Muehlmann4, Cheng-Shi Jiang5.
Abstract
A series of new 1,2,3-triazole derivatives were synthesized and evaluated for anticholinesterase and neuroprotective activities. Some synthetic derivatives, especially compound 32, exhibited improved acetylcholinesterase (AChE) inhibitory activity by comparison with the hit 1, high selectivity toward AChE over butyrylcholinesterase (BuChE), and suitable in vitro neuroprotective effect against amyloid-β25-35 (Aβ25-35)-induced neurotoxicity in SH-SY5Y cells. Furthermore, these molecules have desired physicochemical properties in the range of CNS drugs and showed no cytotoxicity against two normal cells, including human keratinocytes HaCaT and murine fibroblasts NIH-3T3. The preliminary bioassay results and docking study indicated that compound 32 might be a promising lead compound with dual action for the treatment of Alzheimer's disease.Entities:
Keywords: 1,2,3-Triazole; Acetylcholinesterase; Alzheimer’s disease; Amyloid-β-peptide; Neuroprotective
Mesh:
Substances:
Year: 2016 PMID: 27426301 DOI: 10.1016/j.bmcl.2016.07.017
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN: 0960-894X Impact factor: 2.823